Showing 4661-4670 of 9381 results for "".
Evolving Perspectives: The Impact of COVID-19 on the Dermatology Market and Consolidation Activity
https://practicaldermatology.com/topics/practice-management/evolving-perspectives-the-impact-of-covid-19-on-the-dermatology-market-and-consolidation-activity/23347/Experts weigh in on the effect of COVID-19 on Mergers & Acquisitions trends in dermatology.The Microbiome: What Do We Know Now?
https://practicaldermatology.com/topics/atopic-dermatitis/the-microbiome-what-do-we-know-now/23122/Questions and answers about the microbiome and its role in influencing cutaneous health.A Novel Therapeutic Option for the Treatment of Molluscum Contagiosum
https://practicaldermatology.com/topics/general-topics/a-novel-therapeutic-option-for-the-treatment-of-molluscum-contagiosum/21040/There is no FDA approved treatment for molluscum. A novel intervention may erradicate Molluscum with one treatment.Severe Widespread Eczema Mimicking Mycosis Fungoides
https://practicaldermatology.com/topics/atopic-dermatitis/severe-widespread-eczema-mimicking-mycosis-fungoides/85434/Mycosis fungoides, the most common subtype of cutaneous T-cell lymphoma, is well recognized for its ability to mimic a wide array of benign inflammatory dermatoses.Advanced Management Solutions for High-Grade Cutaneous Toxicities to Cancer Therapy
https://practicaldermatology.com/topics/skin-cancer-photoprotection/advanced-management-solutions-for-high-grade-cutaneous-toxicities-to-cancer-therapy/57176/The emergence of immune checkpoint inhibitors (ICIs) has fundamentally altered the prognosis for patients with advanced skin malignancies, yet the high incidence of cutaneous immune-related adverse events (irAEs) remains a significant barrier to treatment continuity. Here, we review the clinical manManagement of Atopic Dermatitis During the COVID-19 Pandemic
https://practicaldermatology.com/topics/atopic-dermatitis/management-of-atopic-dermatitis-during-the-covid-19-pandemic/23322/There is concern about the immunosuppressive or immunomodulatory effects of oral and biologic medications in patients with skin disease.Pearls for Management of Steroid-Responsive Dermatoses
https://practicaldermatology.com/topics/general-topics/pearls-for-management-of-steroid-responsive-dermatoses/21958/From side effects to therapeutic combinations to consider, here is an update on the latest approaches to management of steroid-responsive dermatoses.Diagnosing and Managing Hair Disorders
https://practicaldermatology.com/topics/general-topics/diagnosing-and-managing-hair-disorders/20624/From loss to overgrowth, hair disorders may be associated with systemic causes.Muscle Makers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/muscle-makers/23541/The newest body sculpting technologies show promise for building muscle and strength.Effectiveness of Early Moisturizer Use in Atopic Dermatitis Prevention
https://practicaldermatology.com/issues/novemberdecember-2025/effectiveness-of-early-moisturizer-use-in-atopic-dermatitis-prevention/48889/In the 2025 study by Simpson et al entitled “Emollients to Prevent Pediatric Eczema: A Randomized Clinical Trial,” once-daily, full-body emollient use initiated at 9 weeks of age significantly reduced the cumulative incidence of atopic dermatitis (AD) by 24 months.